DDrare: Database of Drug Development for Rare Diseases

37. 膿疱性乾癬（汎発型）
［臨床試験数：58，薬物数：50（DrugBank：18），標的遺伝子数：17，標的パスウェイ数：96］

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AIN457; AIN457, 150mg; ANAKINRA; ANB019; Acitretin; Adalimumab; Alefacept; Alvarez 2; Anakinra; Anti-IL-36R monoclonal antibody; BI 655130; BI655130; Brodalumab; Brodalumab 210mg SC; CNTO1959; Calcitriol; Certolizumab Pegol; Certolizumab pegol; Efalizumab; GUSELKUMAB; Guselkumab; Guselkumab 100 mg; Infliximab; Infliximab [infliximab biosimilar 3]; Ixekizumab; KHK4827; KHK4827 140mg SC; KHK4827 210mg SC; LY3074828; MONOCLONAL ANTIBODY ANTI-IGG1; Mirikizumab; Null; P32; P32/98; P32/98 3%; Placebo; Raptiva; Risankizumab; SECUKINUMAB; Secukinumab; Secukinumab 150 mg/1 mL Solution for injection; Secukinumab 150mg; Secukinumab 300mg; Silikis 3µg/g Salbe; Spesolimab; TA-650; TG; TREMFYA®; Tremfya; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-003206-58-GB (EUCTR)	29/07/2019	28/05/2019	A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar Psoriasis	A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS	Palmoplantar non-Pustular Psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: TREMFYA ® Product Name: Guselkumab Product Code: CNTO1959 INN or Proposed INN: GUSELKUMAB Other descriptive name: GUSELKUMAB	Janssen-Cilag International N.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	105	Phase 3	France;Spain;Germany;United Kingdom
2	EUCTR2018-003206-58-DE (EUCTR)	02/07/2019	25/04/2019	A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar Psoriasis	A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS	Palmoplantar non-Pustular Psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: TREMFYA ® Product Name: Guselkumab Product Code: CNTO1959 INN or Proposed INN: GUSELKUMAB Other descriptive name: GUSELKUMAB	Janssen-Cilag International N.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	105	Phase 3	France;Spain;Germany;United Kingdom
3	NCT02343744 (ClinicalTrials.gov)	January 19, 2015	16/1/2015	An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis	A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis	Pustular Psoriasis	Drug: Guselkumab	Janssen Pharmaceutical K.K.	NULL	Completed	20 Years	N/A	All	21	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2018-003206-58-GB
(EUCTR)

29/07/2019

28/05/2019

A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar Psoriasis

A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS

Palmoplantar non-Pustular Psoriasis
MedDRA version: 20.0;Level: PT;Classification code 10037153;Term: Psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]

Trade Name: TREMFYA ®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB

Janssen-Cilag International N.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

105

Phase 3

France;Spain;Germany;United Kingdom

EUCTR2018-003206-58-DE
(EUCTR)

02/07/2019

25/04/2019

A Clinical Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar Psoriasis

A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis - G-PLUS

Trade Name: TREMFYA ®
Product Name: Guselkumab
Product Code: CNTO1959
INN or Proposed INN: GUSELKUMAB
Other descriptive name: GUSELKUMAB

Janssen-Cilag International N.V.

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

105

Phase 3

France;Spain;Germany;United Kingdom

NCT02343744
(ClinicalTrials.gov)

January 19, 2015

16/1/2015

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Drug: Guselkumab

Janssen Pharmaceutical K.K.

NULL

Completed

20 Years

N/A

All

Phase 3

Japan